SFX-01 After Subarachnoid Haemorrhage

Trial Profile

SFX-01 After Subarachnoid Haemorrhage

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Sulforafan (Primary)
  • Indications Subarachnoid haemorrhage
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms SAS
  • Sponsors Evgen Pharma
  • Most Recent Events

    • 27 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
    • 27 Feb 2018 Planned primary completion date changed from 1 Apr 2018 to 1 May 2018.
    • 27 Feb 2018 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top